NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Doxycycline to Treat Chlamydial Infection

Phase 4

Recruiting

Conditions: Chlamydial Infection

Interventions: Drug: Doxycycline
Other: Placebo

First Posted Date: 2023-05-03

Last Posted Date: 2025-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 664

Registration Number: NCT05840159

Locations: 🇺🇸
University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States
🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown - Emory Clinic Infectious Diseases, Atlanta, Georgia, United States

and more 4 locations

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

Phase 1

Active, not recruiting

Conditions: HIV-1-infection

Interventions: Biological: INO-6160, 2 mg
Biological: Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)

First Posted Date: 2023-04-25

Last Posted Date: 2024-11-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT05828095

Locations: 🇺🇸
Penn Prevention CRS, Philadelphia, Pennsylvania, United States
🇺🇸
New York Blood Center CRS, New York, New York, United States
🇺🇸
Vanderbuilt Vaccine (VV) CRS, Nashville, Tennessee, United States

L9LS MAb in Malian Adults

Phase 2

Completed

Conditions: Plasmodium Falciparum Infection
Malaria

Interventions: Biological: L9LS (VRC-MALMAB0114-00-AB)
Other: Normal Saline

First Posted Date: 2023-04-18

Last Posted Date: 2024-04-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 288

Registration Number: NCT05816330

Locations: 🇲🇱
Kalifabougou MRTC Clinic, Kalifabougou, Région De Koulikoro, Mali
🇲🇱
Torodo MRTC Clinic, Torodo, Région De Koulikoro, Mali
🇲🇱
Faladje MRTC Clinic, Faladje, Région De Koulikoro, Mali

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

Phase 1

Active, not recruiting

Conditions: HIV Infections

Interventions: Biological: sD-NP-GT8 DNA
Biological: IL-12 DNA
Biological: Trimer 4571
Biological: 3M-052-AF
Drug: Alum

First Posted Date: 2023-03-23

Last Posted Date: 2024-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 46

Registration Number: NCT05781542

Locations: 🇿🇦
Durban Adult HIV CRS, Durban, KwaZulu-Natal, South Africa
🇺🇸
Bridge HIV CRS, San Francisco, California, United States
🇿🇦
Soweto HVTN CRS, Johannesburg, Gauteng, South Africa

and more 5 locations

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: MP0420
Drug: Placebo
Biological: Remdesivir

First Posted Date: 2023-03-22

Last Posted Date: 2024-02-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 485

Registration Number: NCT05780463

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian (Site 080-026), One Hoag Drive, Newport Beach, California, United States
🇺🇸
Emory University (Site 301-008), The Emory Clinic, Bldg. A, Suite 2236, 1365 Clifton Rd., NE, Atlanta, Georgia, United States
🇺🇸
Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard, Fort Wayne, Indiana, United States

and more 102 locations

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Phase 3

Terminated

Conditions: COVID-19

Interventions: Drug: PF-07304814
Drug: Placebo
Biological: Remdesivir

First Posted Date: 2023-03-22

Last Posted Date: 2024-02-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 58

Registration Number: NCT05780541

Locations: 🇺🇸
VA San Diego Healthcare System (Site 074-016), 3350 La Jolla Village Drive, San Diego, California, United States
🇺🇸
University of Utah Hospital (Site 211-002), 419 Wakara Way, Suite 207, Salt Lake City, Utah, United States
🇺🇸
Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States

and more 37 locations

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: VIR-7831
Biological: Placebo
Biological: Remdesivir

First Posted Date: 2023-03-22

Last Posted Date: 2023-12-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 367

Registration Number: NCT05780281

Locations: 🇺🇸
University of Mississippi Medical Center (Site 202-005), 2500 North State Street, Jackson, Mississippi, United States
🇺🇸
UPMC Shadyside Hospital (Site 209-005), 5230 Centre Avenue, Pittsburgh, Pennsylvania, United States
🇺🇸
CHRISTUS Spohn Shoreline Hospital (Site 080-001), 600 Elizabeth Street, Corpus Christi, Texas, United States

and more 102 locations

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: AZD7442
Biological: Placebo
Biological: Remdesivir

First Posted Date: 2023-03-22

Last Posted Date: 2024-07-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1417

Registration Number: NCT05780437

Locations: 🇺🇸
West Virginia University (Site 301-023), One Medical Center Drive, Morgantown, West Virginia, United States
🇺🇸
Hoag Memorial Hospital Presbyterian (Site 080-026), One Hoag Drive, Newport Beach, California, United States
🇺🇸
CHRISTUS Spohn Shoreline Hospital (Site 080-001), 600 Elizabeth Street, Corpus Christi, Texas, United States

and more 121 locations

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: BRII-196
Biological: Placebo
Biological: BRII-198
Biological: Remdesivir

First Posted Date: 2023-03-22

Last Posted Date: 2024-02-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 353

Registration Number: NCT05780424

Locations: 🇺🇸
Baycare Health System (Site 301-025), Morton Plant Hospital, 300 Pinellas Street, Clearwater, Florida, United States
🇺🇸
Memorial Healthcare System (Site 648-002), Memorial Regional Hospital, 3501 Johnson Street, Hollywood, Florida, United States
🇺🇸
Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard, Fort Wayne, Indiana, United States

and more 104 locations

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: LY3819253
Biological: Placebo
Biological: Remdesivir

First Posted Date: 2023-03-22

Last Posted Date: 2023-12-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 314

Registration Number: NCT05780268

Locations: 🇺🇸
UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor, Dallas, Texas, United States
🇺🇸
Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave., Dallas, Texas, United States
🇺🇸
Emory University (Site 301-008), The Emory Clinic, Bldg. A, Suite 2236, 1365 Clifton Rd., NE, Atlanta, Georgia, United States

and more 54 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy